Pharmacoperone drugs: targeting misfolded proteins causing lysosomal storage-, ion channels-, and G protein-coupled receptors-associated conformational disorders
暂无分享,去创建一个
[1] M. Sanguinetti,et al. A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.
[2] Joel L Sussman,et al. Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease. , 2007, The Journal of biological chemistry.
[3] N. Dokholyan,et al. Protein Destabilization as a Common Factor in Diverse Inherited Disorders , 2015, Journal of Molecular Evolution.
[4] David Y. Thomas,et al. Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis. , 2013, Current opinion in chemical biology.
[5] Ernest Beutler,et al. Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[6] Ellen Sidransky,et al. Lysosomal Storage Disorders in the Newborn , 2009, Pediatrics.
[7] P. Conn,et al. Pharmacoperones as a New Therapeutic Approach: In Vitro Identification and In vivo Validation of Bioactive Molecules. , 2016, Current drug targets.
[8] Guangyu Wu,et al. Regulation of Anterograde Transport of α2-Adrenergic Receptors by the N Termini at Multiple Intracellular Compartments* , 2006, Journal of Biological Chemistry.
[9] A. Futerman,et al. Lysosomal storage disorders: old diseases, present and future challenges. , 2013, Pediatric endocrinology reviews : PER.
[10] S. Brothers,et al. 'Effective inefficiency': cellular control of protein trafficking as a mechanism of post-translational regulation. , 2006, The Journal of endocrinology.
[11] Giorgio Colombo,et al. Pharmacological enhancement of α-glucosidase by the allosteric chaperone N-acetylcysteine. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[12] P. Negulescu,et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.
[13] Emily F. Kirby,et al. Enhancing the Potency of F508del Correction: A Multi-Layer Combinational Approach to Drug Discovery for Cystic Fibrosis. , 2013, Journal of pharmacology & clinical toxicology.
[14] H. Dörr,et al. Novel activating mutations of the calcium-sensing receptor: the calcilytic NPS-2143 mitigates excessive signal transduction of mutant receptors. , 2010, The Journal of clinical endocrinology and metabolism.
[15] Richard I. Morimoto,et al. Adapting Proteostasis for Disease Intervention , 2008, Science.
[16] M. Reich,et al. 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors. , 1998, Journal of medicinal chemistry.
[17] N. Leidenheimer,et al. Pharmacological chaperoning: a primer on mechanism and pharmacology. , 2014, Pharmacological research.
[18] W. Gahl,et al. Lysosomal storage diseases , 2016, Translational science of rare diseases.
[19] C. Deber,et al. Misfolding of the cystic fibrosis transmembrane conductance regulator and disease. , 2008, Biochemistry.
[20] S. Brothers,et al. Pharmacologic Rescue of Conformationally‐Defective Proteins: Implications for the Treatment of Human Disease , 2004, Traffic.
[21] K. Hofbauer,et al. Peripheral Administration of a Melanocortin 4-Receptor Inverse Agonist Prevents Loss of Lean Body Mass in Tumor-Bearing Mice , 2006, Journal of Pharmacology and Experimental Therapeutics.
[22] D. Clarke,et al. Chemical and pharmacological chaperones as new therapeutic agents , 2007, Expert Reviews in Molecular Medicine.
[23] S. Angers,et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. , 2000, The Journal of clinical investigation.
[24] N. Dokholyan,et al. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis , 2014, Science Translational Medicine.
[25] Jeffrey L Brodsky,et al. The Recognition and Retrotranslocation of Misfolded Proteins from the Endoplasmic Reticulum , 2008, Traffic.
[26] J. Deng,et al. Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy , 2013, Proceedings of the National Academy of Sciences.
[27] David Y. Thomas,et al. Compounds that correct F508del-CFTR trafficking can also correct other protein trafficking diseases: an in vitro study using cell lines , 2013, Orphanet Journal of Rare Diseases.
[28] Robert J. Desnick,et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. , 2001, The New England journal of medicine.
[29] S. Kaushal,et al. Retinoids Assist the Cellular Folding of the Autosomal Dominant Retinitis Pigmentosa Opsin Mutant P23H* , 2004, Journal of Biological Chemistry.
[30] P. Conn,et al. Salt bridge integrates GPCR activation with protein trafficking , 2010, Proceedings of the National Academy of Sciences.
[31] M. Horie,et al. Novel intracellular transport-refractory mutations in KCNH2 identified in patients with symptomatic long QT syndrome. , 2017, Journal of cardiology.
[32] D. Wolf,et al. ER Degradation of a Misfolded Luminal Protein by the Cytosolic Ubiquitin-Proteasome Pathway , 1996, Science.
[33] A. Cooper,et al. Degradation of misfolded proteins prevents ER-derived oxidative stress and cell death. , 2004, Molecular cell.
[34] P. Conn,et al. Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease , 2009, Molecular and Cellular Endocrinology.
[35] D. Bichet,et al. Pharmacological chaperone action on G-protein-coupled receptors. , 2004, Current opinion in pharmacology.
[36] Hye Kyong Kweon,et al. Glycosylation Quality Control by the Golgi Structure. , 2016, Journal of molecular biology.
[37] N. Johnson,et al. Transmembrane domain quality control systems operate at the endoplasmic reticulum and Golgi apparatus , 2017, PloS one.
[38] J. Flanagan,et al. Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders. , 2011, Assay and drug development technologies.
[39] J. Greer,et al. Structure-Activity Relations of Successful Pharmacologic Chaperones for Rescue of Naturally Occurring and Manufactured Mutants of the Gonadotropin-Releasing Hormone Receptor , 2003, Journal of Pharmacology and Experimental Therapeutics.
[40] P. Conn,et al. G Protein-Coupled Receptor Trafficking in Health and Disease: Lessons Learned to Prepare for Therapeutic Mutant Rescue in Vivo , 2007, Pharmacological Reviews.
[41] E. Zaklyazminskaya,et al. Cardiac channelopathies: genetic and molecular mechanisms. , 2013, Gene.
[42] J. Caramelo,et al. Getting In and Out from Calnexin/Calreticulin Cycles* , 2008, Journal of Biological Chemistry.
[43] Satoshi Omura,et al. Degradation of CFTR by the ubiquitin-proteasome pathway , 1995, Cell.
[44] Xiao-Jing Di,et al. Using pharmacological chaperones to restore proteostasis. , 2014, Pharmacological research.
[45] C. McArdle,et al. Rescue of expression and signaling of human luteinizing hormone G protein-coupled receptor mutants with an allosterically binding small-molecule agonist , 2011, Proceedings of the National Academy of Sciences.
[46] C. January,et al. Novel mechanism associated with an inherited cardiac arrhythmia: defective protein trafficking by the mutant HERG (G601S) potassium channel. , 1999, Circulation.
[47] J. M. Sauder,et al. Impact of the ΔF508 Mutation in First Nucleotide-binding Domain of Human Cystic Fibrosis Transmembrane Conductance Regulator on Domain Folding and Structure* , 2005, Journal of Biological Chemistry.
[48] A. Rolfs,et al. Fabry disease: a review of current management strategies. , 2010, QJM : monthly journal of the Association of Physicians.
[49] P. Conn,et al. Molecular basis of hypogonadotropic hypogonadism: restoration of mutant (E(90)K) GnRH receptor function by a deletion at a distant site. , 2002, The Journal of clinical endocrinology and metabolism.
[50] J. Buchner,et al. The heat shock response: life on the verge of death. , 2010, Molecular cell.
[51] V. Hruby,et al. Contribution of the Conserved Amino Acids of the Melanocortin-4 Receptor in d-[Nle4,Phe7]-α-Melanocyte-stimulating Hormone Binding and Signaling* , 2007, Journal of Biological Chemistry.
[52] A. Minton,et al. Protein aggregation in crowded environments , 2006, Biological chemistry.
[53] D. Bichet,et al. Nephrogenic diabetes insipidus. , 2001, Annual review of physiology.
[54] Y. Tao. Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity , 2005, Molecular and Cellular Endocrinology.
[55] J. Riordan,et al. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing , 1995, Cell.
[56] P. Conn,et al. Misrouted cell surface GnRH receptors as a disease aetiology for congenital isolated hypogonadotrophic hypogonadism. , 2004, Human reproduction update.
[57] F. Hartl,et al. Converging concepts of protein folding in vitro and in vivo , 2009, Nature Structural &Molecular Biology.
[58] R. Fenton,et al. Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment. , 2013, Endocrine reviews.
[59] P. Arvan,et al. Secretory Pathway Quality Control Operating in Golgi, Plasmalemmal, and Endosomal Systems , 2002, Traffic.
[60] J. Robben,et al. Potential of Nonpeptide (Ant)agonists to Rescue Vasopressin V2 Receptor Mutants for the Treatment of X‐linked Nephrogenic Diabetes Insipidus , 2010, Journal of neuroendocrinology.
[61] Patrick Kim Chiaw,et al. Insights into the mechanisms underlying CFTR channel activity, the molecular basis for cystic fibrosis and strategies for therapy. , 2011, Essays in biochemistry.
[62] A. Cooper,et al. ERADicate ER stress or die trying. , 2007, Antioxidants & redox signaling.
[63] Martin L. Duennwald,et al. Small Heat Shock Proteins Potentiate Amyloid Dissolution by Protein Disaggregases from Yeast and Humans , 2012, PLoS biology.
[64] David B. Williams. Beyond lectins: the calnexin/calreticulin chaperone system of the endoplasmic reticulum , 2006, Journal of Cell Science.
[65] H. Schneider. Limitations and Extensions of the Lock-and-Key Principle: Differences between Gas State, Solution and Solid State Structures , 2015, International journal of molecular sciences.
[66] D. Ejima,et al. Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs. , 2006, Biochimica et biophysica acta.
[67] C. January,et al. Molecular pathogenesis of long QT syndrome type 2 , 2016, Journal of arrhythmia.
[68] Shi-Qing Cai,et al. Tetrameric Assembly of K+ Channels Requires ER-Located Chaperone Proteins. , 2017, Molecular cell.
[69] Michel Bouvier,et al. Pharmacological chaperones: potential treatment for conformational diseases , 2004, Trends in Endocrinology & Metabolism.
[70] Vasilis Vasiliou,et al. Human ATP-binding cassette (ABC) transporter family , 2009, Human Genomics.
[71] John P. Overington,et al. How many drug targets are there? , 2006, Nature Reviews Drug Discovery.
[72] Jonathan W. Yewdell,et al. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes , 2000, Nature.
[73] J. Clancy,et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. , 2010, The New England journal of medicine.
[74] J. Meldolesi,et al. BiP, a Major Chaperone Protein of the Endoplasmic Reticulum Lumen, Plays a Direct and Important Role in the Storage of the Rapidly Exchanging Pool of Ca2+ * , 1997, The Journal of Biological Chemistry.
[75] Tommer Ravid,et al. Diversity of degradation signals in the ubiquitin–proteasome system , 2008, Nature Reviews Molecular Cell Biology.
[76] Rahul S. Rajan,et al. A Rhodopsin Mutant Linked to Autosomal Dominant Retinitis Pigmentosa Is Prone to Aggregate and Interacts with the Ubiquitin Proteasome System* , 2002, The Journal of Biological Chemistry.
[77] E. Ingenito,et al. Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del , 2017, The New England journal of medicine.
[78] C. January,et al. Most LQT2 Mutations Reduce Kv11.1 (hERG) Current by a Class 2 (Trafficking-Deficient) Mechanism , 2006, Circulation.
[79] G. Milligan,et al. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists , 2009, Proceedings of the National Academy of Sciences.
[80] S. Brothers,et al. Human loss-of-function gonadotropin-releasing hormone receptor mutants retain wild-type receptors in the endoplasmic reticulum: molecular basis of the dominant-negative effect. , 2004, Molecular endocrinology.
[81] D. Cyr,et al. The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation , 2000, Nature Cell Biology.
[82] John R Yates,et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. , 2010, Nature chemical biology.
[83] N. Bradbury,et al. Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator and Drugs: Insights from Cellular Trafficking. , 2018, Handbook of experimental pharmacology.
[84] M. Welsh,et al. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis , 1993, Cell.
[85] K. Menon,et al. Evidence that palmitoylation of carboxyl terminus cysteine residues of the human luteinizing hormone receptor regulates postendocytic processing. , 2005, Molecular endocrinology.
[86] Andreas Bracher,et al. Molecular chaperones in protein folding and proteostasis , 2011, Nature.
[87] G. Breitwieser,et al. Rescue of Calcium-sensing Receptor Mutants by Allosteric Modulators Reveals a Conformational Checkpoint in Receptor Biogenesis* , 2007, Journal of Biological Chemistry.
[88] Y. Tao. Inactivating mutations of G protein-coupled receptors and diseases: structure-function insights and therapeutic implications. , 2006, Pharmacology & therapeutics.
[89] C. Zuker,et al. Defective intracellular transport is the molecular basis of rhodopsin-dependent dominant retinal degeneration. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[90] J. Yuan,et al. Mutant hERG channel traffic jam. Focus on "Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum". , 2013, American journal of physiology. Cell physiology.
[91] F. Hartl,et al. The role of molecular chaperones in protein folding , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[92] P. Conn,et al. Intracellular Trafficking of G Protein-Coupled Receptors to the Plasma Membrane in Health and Disease , 2014 .
[93] Matthias Griese,et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.
[94] M. Pringle,et al. Folding of a single domain protein entering the endoplasmic reticulum precedes disulfide formation , 2017, The Journal of Biological Chemistry.
[95] N. Pfanner,et al. Protein unfolding by mitochondria , 2000, EMBO reports.
[96] Ping Li,et al. Identification of 2-[2-[2-(5-bromo-2- methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model. , 2004, Journal of medicinal chemistry.
[97] P. Conn,et al. Receptor-misrouting: an unexpectedly prevalent and rescuable etiology in gonadotropin-releasing hormone receptor-mediated hypogonadotropic hypogonadism. , 2002, The Journal of clinical endocrinology and metabolism.
[98] C. January,et al. Correction of Defective Protein Trafficking of a Mutant HERG Potassium Channel in Human Long QT Syndrome , 1999, The Journal of Biological Chemistry.
[99] Chris Fellner,et al. CFTR Modulators for the Treatment of Cystic Fibrosis. , 2014, P & T : a peer-reviewed journal for formulary management.
[100] S. Lindquist,et al. Hsp104, Hsp70, and Hsp40 A Novel Chaperone System that Rescues Previously Aggregated Proteins , 1998, Cell.
[101] Xiaohong Huang,et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.
[102] Michel Bouvier,et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. , 2005, Journal of the American Society of Nephrology : JASN.
[103] Canhui Li,et al. A Small-Molecule Modulator Interacts Directly with ΔPhe508-CFTR to Modify Its ATPase Activity and Conformational Stability , 2009, Molecular Pharmacology.
[104] H. Kampinga,et al. The HSP70 chaperone machinery: J proteins as drivers of functional specificity , 2010, Nature Reviews Molecular Cell Biology.
[105] T. Spicer,et al. Assay strategies for identification of therapeutic leads that target protein trafficking. , 2015, Trends in pharmacological sciences.
[106] G. Robertson,et al. HERG, a human inward rectifier in the voltage-gated potassium channel family. , 1995, Science.
[107] P. Harmatz. Enzyme Replacement Therapies and Immunogenicity in Lysosomal Storage Diseases: Is There a Pattern? , 2015, Clinical therapeutics.
[108] A. Cavanaugh,et al. Pharmacochaperone-mediated rescue of calcium-sensing receptor loss-of-function mutants. , 2009, Molecular endocrinology.
[109] P. Deen,et al. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus. , 2007, American journal of physiology. Renal physiology.
[110] K. Loeb,et al. Multiple mutations and cancer , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[111] R. Kaufman,et al. The impact of the unfolded protein response on human disease , 2012, The Journal of cell biology.
[112] P. Conn,et al. Drug development and the cellular quality control system. , 2009, Trends in pharmacological sciences.
[113] A. Cavanaugh,et al. Calcium-sensing Receptor Biosynthesis Includes a Cotranslational Conformational Checkpoint and Endoplasmic Reticulum Retention* , 2010, The Journal of Biological Chemistry.
[114] L. Tsui,et al. Erratum: Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA , 1989, Science.
[115] C. Timossi,et al. Structure-function relationship of follicle-stimulating hormone and its receptor. , 1998, Human reproduction update.
[116] D. Ron,et al. Conformational disease , 2000, Nature Cell Biology.
[117] J. Sambrook,et al. Protein folding in the cell , 1992, Nature.
[118] S. Ishii,et al. Pharmacological chaperone therapy for Fabry disease , 2012, Proceedings of the Japan Academy. Series B, Physical and biological sciences.
[119] C. Timossi,et al. Biochemical and functional aspects of gonadotrophin-releasing hormone and gonadotrophins. , 2000, Reproductive biomedicine online.
[120] P. Conn,et al. Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptors. , 2011, Advances in pharmacology.
[121] Satoshi Ishii,et al. Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitor , 1999, Nature Medicine.
[122] P. Michael Conn,et al. Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs , 2010, Trends in Endocrinology & Metabolism.
[123] Y. Tao. The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. , 2010, Endocrine reviews.
[124] Christopher M Dobson,et al. Principles of protein folding, misfolding and aggregation. , 2004, Seminars in cell & developmental biology.
[125] P. Compain,et al. Alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease. , 2006, Bioorganic & medicinal chemistry.
[126] Shuxia Zhao,et al. The Binding Site for Channel Blockers That Rescue Misprocessed Human Long QT Syndrome Type 2 ether-a-gogo-related Gene (HERG) Mutations* , 2002, The Journal of Biological Chemistry.
[127] Y. Tao,et al. A Small Molecule Agonist THIQ as a Novel Pharmacoperone for Intracellularly Retained Melanocortin-4 Receptor Mutants , 2014, International journal of biological sciences.
[128] P. Conn,et al. Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function , 2014, Molecular and Cellular Endocrinology.
[129] Kai Du,et al. The ΔF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR , 2005, Nature Structural &Molecular Biology.
[130] Hong Yu Ren,et al. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1 , 2013, Molecular biology of the cell.
[131] David Y. Thomas,et al. Novel pharmacological strategies to treat cystic fibrosis. , 2013, Trends in pharmacological sciences.
[132] Zayd M. Khaliq,et al. A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism , 2016, The Journal of Neuroscience.
[133] A. Nakano,et al. Membrane protein retrieval from the Golgi apparatus to the endoplasmic reticulum (ER): characterization of the RER1 gene product as a component involved in ER localization of Sec12p. , 1995, Molecular biology of the cell.
[134] Ying Wang,et al. Correctors Promote Maturation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)-processing Mutants by Binding to the Protein* , 2007, Journal of Biological Chemistry.
[135] Jean A Castillo-Badillo,et al. Role of Cysteine Residues in the Carboxyl-Terminus of the Follicle-Stimulating Hormone Receptor in Intracellular Traffic and Postendocytic Processing , 2016, Front. Cell Dev. Biol..
[136] M. Welsh,et al. Structure and function of the CFTR chloride channel. , 1999, Physiological reviews.
[137] P. Deen,et al. Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus. , 2006, American journal of physiology. Renal physiology.
[138] B. Baldo,et al. Enzymes Approved for Human Therapy: Indications, Mechanisms and Adverse Effects , 2015, BioDrugs.
[139] Ying Wang,et al. Specific Rescue of Cystic Fibrosis Transmembrane Conductance Regulator Processing Mutants Using Pharmacological Chaperones , 2006, Molecular Pharmacology.
[140] D. Bichet,et al. Pharmacological chaperones: a new twist on receptor folding. , 2000, Trends in pharmacological sciences.
[141] T. Rush,et al. Molecular mechanism of action of pharmacoperone rescue of misrouted GPCR mutants: the GnRH receptor. , 2009, Molecular endocrinology.
[142] B. Papsin,et al. Misfolding diverts CFTR from recycling to degradation , 2004, The Journal of cell biology.
[143] Ari Helenius,et al. Quality control in the endoplasmic reticulum , 2003, Nature Reviews Molecular Cell Biology.
[144] F. Hartl,et al. Molecular Chaperones in the Cytosol: from Nascent Chain to Folded Protein , 2002, Science.
[145] P. Conn,et al. In vitro coexpression and pharmacological rescue of mutant gonadotropin-releasing hormone receptors causing hypogonadotropic hypogonadism in humans expressing compound heterozygous alleles. , 2005, The Journal of clinical endocrinology and metabolism.
[146] C. January,et al. HERG Channel Dysfunction in Human Long QT Syndrome , 1998, The Journal of Biological Chemistry.
[147] R. Kaufman,et al. A trip to the ER: coping with stress. , 2004, Trends in cell biology.
[148] A. Aiuti,et al. Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I , 2017, Journal of Inherited Metabolic Disease.
[149] Y. Tao,et al. Pharmacological chaperones for the misfolded melanocortin-4 receptor associated with human obesity. , 2017, Biochimica et biophysica acta. Molecular basis of disease.
[150] Kirby Ef,et al. Enhancing the Potency of F508del Correction: A Multi-Layer Combinational Approach to Drug Discovery for Cystic Fibrosis. , 2013 .
[151] Jason C. Young,et al. Pathways of chaperone-mediated protein folding in the cytosol , 2004, Nature Reviews Molecular Cell Biology.
[152] Jonathan Weissman,et al. Molecular Chaperones and Protein Quality Control , 2006, Cell.
[153] P. Conn,et al. Chaperoning G protein-coupled receptors: from cell biology to therapeutics. , 2014, Endocrine reviews.
[154] C. Bear,et al. Probing Conformational Rescue Induced by a Chemical Corrector of F508del-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutant* , 2011, The Journal of Biological Chemistry.
[155] V. Hruby,et al. Contribution of the conserved amino acids of the melanocortin-4 receptor in [corrected] [Nle4,D-Phe7]-alpha-melanocyte-stimulating [corrected] hormone binding and signaling. , 2007, The Journal of biological chemistry.
[156] J. Stirnemann,et al. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments , 2017, International journal of molecular sciences.
[157] A. Rzhetsky,et al. The human ATP-binding cassette (ABC) transporter superfamily. , 2001, Genome research.
[158] P. Deen,et al. Rescue of vasopressin V2 receptor mutants by chemical chaperones: specificity and mechanism. , 2005, Molecular biology of the cell.
[159] David Y. Thomas,et al. Lectin control of protein folding and sorting in the secretory pathway. , 2003, Trends in biochemical sciences.
[160] G. Durand,et al. Normal testicular function without detectable follicle-stimulating hormone. A novel mutation in the follicle-stimulating hormone receptor gene leading to apparent constitutive activity and impaired agonist-induced desensitization and internalization , 2012, Molecular and Cellular Endocrinology.
[161] D. Krainc,et al. α-Synuclein–induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models , 2016, Proceedings of the National Academy of Sciences.
[162] E. Abel,et al. Lipids, lysosomes, and autophagy , 2016, Journal of Lipid Research.
[163] J. Gustafson,et al. Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.
[164] Daniel C Bartos,et al. Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum. , 2013, American journal of physiology. Cell physiology.
[165] Zhen‐Chuan Fan,et al. Functional characterization and pharmacological rescue of melanocortin-4 receptor mutations identified from obese patients , 2009, Journal of cellular and molecular medicine.
[166] T. Gudermann,et al. Mutations of the human thyrotropin receptor gene causing thyroid hypoplasia and persistent congenital hypothyroidism. , 1997, The Journal of clinical endocrinology and metabolism.
[167] Christine E. Bear,et al. A Chemical Corrector Modifies the Channel Function of F508del-CFTR , 2010, Molecular Pharmacology.
[168] Guillaume Godin,et al. Design and Synthesis of Highly Potent and Selective Pharmacological Chaperones for the Treatment of Gaucher's disease , 2006, Chembiochem : a European journal of chemical biology.
[169] G. Lukács,et al. Protein quality control at the plasma membrane. , 2011, Current opinion in cell biology.
[170] P. H. Cameron,et al. The endoplasmic reticulum: integration of protein folding, quality control, signaling and degradation. , 2001, Current opinion in structural biology.
[171] Marcel Hibert,et al. Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus. , 2009, Journal of the American Society of Nephrology : JASN.
[172] F. Ratjen. Cystic fibrosis: pathogenesis and future treatment strategies. , 2009, Respiratory care.
[173] P. Conn,et al. Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases. , 2018, Physiological reviews.
[174] S. Persaud,et al. Cellular Endocrinology in Health and Disease , 2014 .
[175] R. Brady,et al. Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function , 2011, Proceedings of the National Academy of Sciences.
[176] F. Pinet,et al. Functional Characterization of Three Mutations of the Endothelin B Receptor Gene in Patients With Hirschsprung’s Disease: Evidence for Selective Loss of Gi Coupling , 2001, Molecular medicine.
[177] A. Wilde,et al. Inherited ion channel diseases: a brief review. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[178] B. Wiesner,et al. Pharmacochaperones Post-translationally Enhance Cell Surface Expression by Increasing Conformational Stability of Wild-type and Mutant Vasopressin V2 Receptors* , 2004, Journal of Biological Chemistry.
[179] J. Greer,et al. Refolding of misfolded mutant GPCR: Post-translational pharmacoperone action in vitro , 2007, Molecular and Cellular Endocrinology.
[180] A. Helenius,et al. ER quality control: towards an understanding at the molecular level. , 2001, Current opinion in cell biology.
[181] S. Garland. Are GPCRs Still a Source of New Targets? , 2013, Journal of biomolecular screening.
[182] A. Helenius,et al. Roles of N-linked glycans in the endoplasmic reticulum. , 2004, Annual review of biochemistry.
[183] A. Verkman,et al. Cystic fibrosis transmembrane regulator correctors and potentiators. , 2013, Cold Spring Harbor perspectives in medicine.
[184] D. Niu,et al. Fabry disease: Review and experience during newborn screening. , 2017, Trends in cardiovascular medicine.
[185] A. Parodi,et al. Quality control and protein folding in the secretory pathway. , 2003, Annual review of cell and developmental biology.
[186] D. Krainc,et al. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons , 2016, The Journal of Neuroscience.
[187] A. Cooper,et al. Misfolded proteins traffic from the endoplasmic reticulum (ER) due to ER export signals. , 2006, Molecular biology of the cell.
[188] A. J. Parodi,et al. Role of N-oligosaccharide endoplasmic reticulum processing reactions in glycoprotein folding and degradation. , 2000, The Biochemical journal.
[189] S. Noel,et al. Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives , 2016, Clinical pharmacology : advances and applications.
[190] H. Katus,et al. Defective protein trafficking in hERG-associated hereditary long QT syndrome (LQT2): molecular mechanisms and restoration of intracellular protein processing. , 2003, Cardiovascular research.
[191] Astha Koolwal,et al. Ivacaftor: a novel mutation modulating drug. , 2014, Journal of clinical and diagnostic research : JCDR.
[192] D. Clarke,et al. Rescue of Folding Defects in ABC Transporters Using Pharmacological Chaperones , 2005, Journal of bioenergetics and biomembranes.
[193] Rohan Dandage,et al. Classification of chemical chaperones based on their effect on protein folding landscapes. , 2015, ACS chemical biology.
[194] S. Weindling,et al. Inherited arrhythmias: The cardiac channelopathies , 2015, Annals of pediatric cardiology.
[195] M. Birnbaumer. V2R structure and diabetes insipidus. , 2002, Receptors & channels.
[196] Melanie A. Jones,et al. Mechanisms of Pharmacological Rescue of Trafficking-defective hERG Mutant Channels in Human Long QT Syndrome* , 2006, Journal of Biological Chemistry.
[197] C. January,et al. Thapsigargin Selectively Rescues the Trafficking Defective LQT2 Channels G601S and F805C* , 2003, Journal of Biological Chemistry.